Receive News Stock Ratings for GW Pharmaceuticals PLC- Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GW Pharmaceuticals PLC- and related stocks with our FREE daily email newsletter. … read more at: https://www.thecerbatgem.com/2017/05/11/gw-pharmaceuticals-plc-gwph-receives-new-coverage-from-analysts-at-maxim-group-updated-updated.html

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

DEVON, Pa., May 09, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of recent operational highlights. “This quarter, we were very pleased to have […]

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

DEVON, Pa., May 09, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of recent operational highlights. “This quarter, we were very pleased to have […]

– Epidiolex® NDA submission expected mid-year –– New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology –– Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics […]

DEVON, Pa., May 09, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of recent operational highlights. “This quarter, we were very pleased to have […]

Perth, May 9, 2017 AEST (ABN Newswire) – MMJ PhytoTech Limited (ASX:MMJ) (“MMJ” or “the Company”) is pleased to advise that the Company’s Australian distribution partner, Melbourne-based HL Pharma Pty Ltd. (“HL Pharma”), has successfully imported its first shipment of medicinal products from the Company’s Swiss-subsidiary, Satipharm AG, (“Satipharm”). – HL Pharma Pty Ltd successfully […]

LONDON, May 02, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 May, 2017 its second quarter financial results for the period ending 31 March, 2017. GW will also host a […]